BONESUPPORT AB (STO:BONEX), an orthobiologics company focused on the management of bone voids, announced on Friday the publication of ground-breaking data on bone remodelling of CERAMENT in pre-clinical model.

This study, entitled 'Establishment and effects of allograft and synthetic bone graft substitute treatment of a critical size metaphyseal bone defect model in the sheep femur' is published in APMIS (Acta Pathologica, Microbiologica et Immunologica Scandinavica) Journal of Pathology, Microbiology and Immunology.

Dr Michael Diefenbeck, the company's EVP R&D, Medical & Clinical Affairs, is the senior author of the publication

Reportedly, this pilot study represents an important initial step towards establishing a clinically relevant large animal model that allows thorough investigation of bone graft substitute-mediated bone defect regeneration, in-depth analysis of its interaction with host bone and accurate documentation of the resulting bone remodelling over time.

Also, the combination of different imaging methods like radiographs, μCT, MRI and histology provides a clearer insight into the healing process of the bone tissue. Histological evaluations helped to confirm the resorption of CERAMENT and regeneration of trabecular bone in the periphery of the void as early as three months.

According to the company, this research was performed in collaboration with authors from the Universities in Copenhagen, Munich and Jena, namely Dr Werner Hettwer, Dr Peter Horstmann, Dr Sabine Bischoff, Dr Daniel Güllmar, Prof Jürgen Reichenbach, Dr Patrina Su Ping Poh, Prof Martijn van Griensven and Dr Florian Gras.

Bone support Holding develops and commercialises innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. The company's bone graft substitutes are based on the patented technology platform CERAMENT.